BMRN (BioMarin Pharmaceutical Inc) Technical Analysis

BMRN Technical Analysis leverages historical price and volume data to provide real-time indicator values and signals, including RSI, MACD, Bollinger Bands, and volume, to reflect market momentum, volatility ranges, and price-volume dynamics. It also integrates market sentiment metrics such as the VIX volatility index, Advance-Decline ratio (A/D ratio), and Put/Call options ratio for broader market context. Multi-timeframe views span from minute intervals to daily, weekly, and monthly charts, making it easy to track indicator behavior across periods. Key support and resistance levels are displayed alongside current prices, calculated via pivots, Fibonacci retracements, and historical extremes to offer an immediate overview of market structure.
BMRN
BMRN

BioMarin Pharmaceutical Inc

$57.77+1.15%
Today's High$58.48
Today's Low$57.19
Today's Open$57.19
Yesterday's Close$57.11

BMRN (BioMarin Pharmaceutical Inc) Technical Analysis Overview

AI CreationAs of July 1, 2026, BioMarin Pharmaceutical Inc (BMRN) is showing neutral-to-bullish momentum. The MACD reading of 0.8678 carries a buy signal implying sustained upside momentum, the RSI(14) at 56.5366 indicates neutral-to-strong momentum in the 45–70 range without overbought extremes, and the moving average framework displays 13 buy signals against 1 sell signal on the daily timeframe, confirming short-term directional conviction. The Average Directional Index (14) stands at 24.9056 with a neutral signal, suggesting the trend is beginning to strengthen from consolidation. Overall, the technical structure reflects a transition phase where short-term support remains intact but medium-term directional persistence requires confirmation above near-term resistance levels.

Oscillators

Strong Sell
Strong Buy
Buy
0
Sell
9
Neutral
2
Buy

Summary

Strong Sell
Strong Buy
Buy
1
Sell
10
Neutral
15
Buy

Moving Averages

Strong Sell
Strong Buy
Strong Buy
1
Sell
1
Neutral
13
Buy

BMRN (BioMarin Pharmaceutical Inc) Live Candlestick Chart

BMRN (BioMarin Pharmaceutical Inc) Multi-Timeframe Technical Rating

Summary1H4H1D1W
Moving Averages (15)131140131104
Oscillators (11)NeutralNeutralNeutralNeutral
RSI (14)52.957.557.953.4
MACD (12,26)Golden CrossGolden CrossGolden CrossDeath Cross

BMRN (BioMarin Pharmaceutical Inc) Technical Indicator Interpretation

Based on 1-day closing price series

Oscillators

NameValueOperation
RSI(14)
57.9288Neutral
Stochastic %K (14, 3, 3)
60.1331Neutral
Commodity Channel Index (CCI) (20)
101.0626Neutral
Average Directional Index (ADX) (14)
25.6095Neutral
Awesome Oscillator (AO)
2.7574Neutral
Momentum Indicator (10)
2.71Buy
MACD Level (12, 26)
0.874Buy
Stochastic RSI Fast (3, 3, 14, 14)
52.4573Neutral
Williams Percent Range (%R) (14)
-35.2087Neutral
Bull Bear Power (BBP)
2.0976Neutral
Ultimate Oscillator (UO) (7, 14, 28)
52.5111Neutral

Moving Averages

NameValueOperation
EMA (10)
57.1073Buy
SMA (10)
56.851Buy
EMA (20)
56.3747Buy
SMA (20)
56.465Buy
EMA (30)
55.9157Buy
SMA (30)
55.3713Buy
EMA (50)
55.5989Buy
SMA (50)
54.6313Buy
EMA (100)
55.7445Buy
SMA (100)
56.3239Buy
EMA (200)
56.7344Buy
SMA (200)
55.7083Buy
Ichimoku Kinko Hyo Base Line (9, 26, 52, 26)
55.9825Neutral
Volume-Weighted Moving Average (VWMA) (20)
56.5127Buy
Hull Moving Average (HMA) (9)
58.1601Sell

BMRN (BioMarin Pharmaceutical Inc) Pivot Points

Based on 1-day timeframe

PriceClassicFibonacciCamarillaWoodieDM
R370.186763.426759.07967.61-
R263.426760.844358.459363.69-
R160.323359.24957.839760.8561.875
Pivot P56.666756.666756.666756.9357.4425
S153.563354.084356.600354.0955.115
S249.906752.48955.980750.17-
S343.146749.906755.36147.33-

BMRN (BioMarin Pharmaceutical Inc) Market Sentiment Index

Analyst Rating87.8461
Options Put/Call Ratio+30.07%
Implied Volatility (IV)43.3664

BMRN (BioMarin Pharmaceutical Inc) Deep Technical Analysis

As of July 1, 2026, BioMarin Pharmaceutical Inc (BMRN) is exhibiting a neutral-to-bullish technical structure with price action at 57.31, positioned above key short-term moving averages. The **BMRN technical analysis** shows a MACD indicator at 0.8678 with a buy signal, implying sustained upside momentum, while the RSI(14) reading of 56.5366 places the stock in the neutral-to-strong zone (45–70 range), confirming that bullish forces maintain equilibrium without reaching overbought extremes. The daily price range (high 57.60, low 56.32) reflects a relatively tight consolidation, typical of a market in transition between established uptrend and potential breakout phase. The Average Directional Index (14) stands at 24.9056 with a neutral signal, indicating that trend strength is beginning to emerge from a period of consolidation and suggesting moderate trend persistence. The Commodity Channel Index (20) reading of 66.2324 carries a neutral signal, while the Momentum (10) indicator at 1.75 carries a buy signal, reinforcing that short-term acceleration remains intact and the overall directional bias tilts upward despite some moderating pressure in the near term. The moving average system demonstrates strong bullish alignment, with EMA10 at 56.9795, EMA20 at 56.2386, and EMA50 at 55.5149 all carrying buy signals and positioned closely together, confirming short-term upside bias. The SMA200 at 55.6905 also maintains a buy signal, indicating that the longer-term trend structure remains supportive of higher prices. Price action near 57.31 is trading above all major moving averages, which serve as dynamic support; the BMRN market analysis is in a transitional phase where medium-term support is being tested rather than decisively confirmed, with the interleaved arrangement of these averages suggesting buyers remain in control. resistance targets are positioned at 57.8382 (R1), 59.7854 (R2), and 62.9372 (R3), while support levels are anchored at 51.5346 (S1), 49.5874 (S2), and 46.4356 (S3). The current price of 57.31 sits below the first resistance level, suggesting that the near-term BMRN price forecast depends on whether buyers can sustain momentum above R1 or whether profit-taking emerges at the current consolidation zone. The Camarilla pivot framework offers tighter levels, with support at 56.5337 (S1) and resistance at 58.0463 (R1), providing intraday reference points for traders managing risk. On the market breadth front, analyst sentiment toward BMRN is decidedly positive, with an analyst rating of 87.8461 indicating strong institutional optimism. The implied volatility reading of 49.2874 suggests elevated option premium pricing and a market environment where participants are pricing in meaningful price movement. The Put/Call ratio of 62.3 indicates that put options are trading at notably elevated levels relative to calls, reflecting hedging demand or risk aversion among options traders despite the bullish fundamental backdrop. Overall, the near-term BMRN price prediction remains shaped by the tension between bullish moving average alignment and the requirement for a breakout above R1 to sustain conviction, with sentiment tilted constructively but technical confirmation requiring a decisive close above the first resistance level.

FAQ

What is the current technical rating for BMRN?

x
On the 4H timeframe, the aggregate technical rating for BMRN is Buy. This rating is dynamically aggregated from moving averages and momentum oscillators to reflect the prevailing trend direction and price velocity.

Where are the key support and resistance levels for BMRN?

x

What are the current RSI and MACD signals for BMRN?

x

How often is the BMRN technical analysis data updated?

x

Continue Exploring BMRN (BioMarin Pharmaceutical Inc)

Risk Warning:

Traditional finance such as forex and CFDs may experience significant price fluctuations. Past performance is not a reliable indicator of future results. The vast majority of retail client accounts incur losses when trading forex and CFDs. Please ensure you fully understand how forex and CFDs operate and assess whether you are able to bear the risk of substantial losses. Even with stop-loss orders, your losses may exceed your initial deposit. Therefore, you should not engage in speculative trading with funds you cannot afford to lose, and you should ensure you are fully aware of the risks involved. The information provided by Gate is general in nature and does not take into account your investment objectives, financial situation, or specific needs. The content and prices on this website must not be interpreted as personal investment advice. Please ensure you fully understand the risks involved and seek independent professional advice where necessary. Gate reserves the right to terminate services at its sole discretion at any time. Gate is not liable for any losses resulting from such termination, including losses caused by closing positions at unfavorable market prices or forced liquidation. For more information, please refer to our Risk Warning.

Disclaimer:

Gate only provides trade execution services. Any information, reports, opinions, comments, or other materials obtained from Gate, its employees, Gate-provided analytical tools, or third-party research do not constitute investment advice and should not be relied upon for investment decisions. You agree to do your own research and verify external information sources before making any investment. You further agree that Gate shall not be held liable for any loss or damage (including but not limited to loss of profits) arising directly or indirectly from the use of or reliance on such information. Nothing contained in any reports shall be interpreted as an explicit or implied promise, guarantee, or indication of profit, nor does it guarantee that losses can be limited or avoided. Please also note that data related to traditional finance such as forex and CFDs (e.g., real-time prices) displayed on this page is sourced from third parties, is provided for reference only, and is offered on an "as-is" basis without any representations or warranties of any kind, express or implied. Any third-party website links provided are not under Gate's control. Gate assumes no responsibility for the reliability or accuracy of such third-party websites or their content. For further details, please refer to our User Agreement.